Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance

Emi Takashita1

  • 1Influenza Virus Research Center, National Institute of Infectious Diseases, Musashimurayama, Tokyo 208-0011, Japan.

Insights

Influenza virus polymerase inhibitors like favipiravir, pimodivir, and baloxavir marboxil target essential viral replication proteins. This review examines their mechanisms, efficacy, and resistance for influenza treatment.

Area of Science:

  • Virology
  • Pharmacology

Background:

  • The influenza virus RNA-dependent RNA polymerase is a conserved, essential target for antiviral development.
  • It consists of subunits PB1, PB2, and PA (influenza A/B) or P3 (influenza C/D).

Purpose of the Study:

  • To review the mechanism of action, antiviral activity, and resistance of key influenza polymerase inhibitors.
  • To discuss favipiravir (PB1 inhibitor), pimodivir (PB2 inhibitor), and baloxavir marboxil (PA inhibitor).

Main Methods:

  • Literature review of scientific publications and clinical trial data.
  • Analysis of inhibitor mechanisms, efficacy against influenza viruses, and resistance profiles.

Main Results:

  • Favipiravir, pimodivir, and baloxavir marboxil demonstrate varying antiviral activities and resistance emergence patterns.
  • Each inhibitor targets a specific subunit of the influenza polymerase, impacting viral replication.

Conclusions:

  • Influenza polymerase inhibitors represent a promising therapeutic strategy against influenza infections.
  • Understanding their mechanisms and resistance is crucial for effective clinical application and future drug development.

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.4K
Leaky Scanning02:28

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.5K
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
162
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.8K